Chiropractors in Ipswich, MA Accepting Medicare
6 Chiropractors found. Showing 1 - 6
 Back To Normal Chiropractic, Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 78 Central St, Unit 3, Ipswich, MA 01938 Phone: 978-317-6756 Fax: 978-412-9099 |
 Dr. David Clive Beckingham, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 64 County Rd, Ipswich, MA 01938 Phone: 978-356-3979 Fax: 978-356-5792 |
Dr. Paul S. Scioli, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 130 County Rd., Suite L., Ipswich, MA 01938 Phone: 978-356-7888 |
Dr. Swiatoslaw Alexander Paduchak, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 78 Central St, Unit 3, Ipswich, MA 01938 Phone: 978-317-6756 Fax: 978-412-9099 |
Wynne Chiropractic & Wellness Chiropractor Medicare: Medicare Enrolled Practice Location: 1 Topsfield Rd, Ipswich, MA 01938 Phone: 508-274-9772 |
Spinal Therapy & Rehabilitation Pc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 77 Turnpike Rd, Ipswich, MA 01938 Phone: 978-356-5525 Fax: 978-356-5584 |
News Archive
ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).
Scientists discover extremely long-lived proteins in aging rats
One of the big mysteries in biology is why cells age. Now scientists at the Salk Institute for Biological Studies report that they have discovered a weakness in a component of brain cells that may explain how the aging process occurs in the brain.
Three key technologies receive £85 million investment for capital equipment from EPSRC
Three key technologies, identified in the pre-budget statement by The Chancellor of the Exchequer as part of the government's 'eight great technologies' to drive UK growth, are to receive an -85 million investment for capital equipment.
Bruker Corporation revenue increases by 9.5% in third-quarter 2009
Bruker Corporation today reported financial results for the third quarter ended September 30, 2009.
› Verified 3 days ago
Physical Therapists
Occupational Therapists
Chiropractors
Speech-Language Pathologists
Optometrists